Evidence map›Paper›PMID 35847443›Full record

ArticleAnnals of gastroenterological surgery2022

Detection of secondary upper gastrointestinal tract cancer during follow-up esophagogastroduodenoscopy after gastrectomy for gastric cancer.

Kosuke Nakane, Keiichi Fujiya, Masanori Terashima, Takanori Kawabata, Yosuke Matsumoto, Satoshi Kamiya, Makoto Hikage, Yutaka Tanizawa, Hiroyuki Ono, Etsuro Bando

Open access · goldAbstract read
In one paragraph

Article in Annals of gastroenterological surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Annals of gastroenterological surgery · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kosuke NakaneDivision of Gastric Surgery Shizuoka Cancer Center Nagaizumi Japan.
Keiichi FujiyaDivision of Gastric Surgery Shizuoka Cancer Center Nagaizumi Japan.
Masanori TerashimaDivision of Gastric Surgery Shizuoka Cancer Center Nagaizumi Japan.ORCID https://orcid.org/0000-0002-2967-8267
Takanori KawabataClinical Research Center Shizuoka Cancer Center Nagaizumi Japan.
Yosuke MatsumotoDivision of Gastric Surgery Shizuoka Cancer Center Nagaizumi Japan.
Satoshi KamiyaDivision of Gastric Surgery Shizuoka Cancer Center Nagaizumi Japan.
Makoto HikageDivision of Gastric Surgery Shizuoka Cancer Center Nagaizumi Japan.
Yutaka TanizawaDivision of Gastric Surgery Shizuoka Cancer Center Nagaizumi Japan.
Hiroyuki OnoDivision of Endoscopy Shizuoka Cancer Center Nagaizumi Japan.
Etsuro BandoDivision of Gastric Surgery Shizuoka Cancer Center Nagaizumi Japan.
Shizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Esophagogastroduodenoscopy (EGD) may contribute to early detection of secondary cancer in the upper gastrointestinal tract although the clinical relevance of follow-up after gastrectomy remains unclear. This study aimed to elucidate the effectiveness of follow-up EGD by investigating the incidence of secondary cancer in any part of the upper gastrointestinal tract. Methods: Data from 1438 patients who underwent curative partial gastrectomy for primary gastric cancer between 2008 and 2014 and follow-up EGD at least once during a 5-year follow-up period were retrospectively reviewed. Incidence rates of remnant gastric cancer, laryngeal cancer, and esophageal cancer detected after follow-up EGD were determined, and risk factors for secondary cancers were examined. The characteristics of clinicopathological diagnoses of secondary cancers were reviewed and compared according to the frequency of follow-up EGD. Results: The average annual frequency of EGD was 0.7, while the 5-year cumulative incidence rates of remnant gastric cancer and secondary laryngeal and esophageal cancers were 2.9% and 1.3%, respectively. Risk factors for remnant gastric cancer included heavy smoking, proximal gastrectomy, and tumor size ≥ 30 mm. All secondary cancers were resectable upon diagnosis, with endoscopically resectable cancer accounting for 81.0% of cases. Our results found a significantly higher proportion of endoscopically resectable cancers during regular follow-up than during infrequent follow-up. Conclusions: Follow-up EGD can be a useful modality for detecting secondary upper gastrointestinal tract cancer, likely leading to curative treatment for secondary cancer. Focusing on patients presenting with risk factors may increase the value of follow-up EGD after gastrectomy.

Indexed as

Fine and Gray modelfollow‐up EGDgastrectomyremnant gastric cancersecondary cancer

Identifiers

PMID35847443
PMCPMC9271028
OpenAlexW4210337297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.